Skip to main content

Table 2 Postoperative data from groups 1 and 2 during the first year from Ahmed glaucoma valve implantation

From: Visual prognosis and surgical timing of Ahmed glaucoma valve implantation for neovascular glaucoma secondary to diabetic vitrectomy

 

Total

(n = 35)

Group 1

(n = 16)

Group 2

(n = 19)

P-value

Post-AGVI BCVA

1.22 ± 0.79

1.21 ± 0.69

1.25 ± 0.86

0.961†

Unfavorable visual outcome (%)

12 (34.3)

7 (43.8)

5 (26.3)

0.311‡

IOP at the time of AGVI (mmHg)

36.8 ± 9.36

41.3 ± 7.4

33.1 ± 9.2

0.003†

Postoperative IOP

    

3 months after AGVI

17.9 ± 7.1

17.8 ± 9.7

18.0 ± 3.6*

0.108†

6 months after AGVI

17.6 ± 6.1**

16.3 ± 3.7*

18.7 ± 7.3*

0.513†

12 months after AGVI

15.2 ± 4.0**

14.5 ± 3.7*

15.7 ± 4.2*

0.327†

Surgical success at one year based on IOP (%)

30 (85.7)

13 (81.3)

17 (89.5)

0.642‡

Complications (%)

    

Anterior chamber hyphema

6 (17.1)

3 (18.8)

3 (15.8)

1.000‡

Tube obstruction

1 (2.9)

1 (6.3)

0 (0)

0.457‡

Vitreous hemorrhage

8 (22.9)

4 (25.0)

4 (21.1)

1.000‡

Early hypotony with choroidal detachment

or collapsed anterior chamber

1 (2.9)

1 (6.3)

0 (0)

0.441‡

Endophthalmitis

0 (0)

0 (0)

0 (0)

1.000‡

  1. *Except for one case who underwent re-AGVI
  2. **Except for two cases who underwent re-AGVI
  3. † Calculated using an independent t-test and Mann Whitney test
  4. ‡ Calculated using a Chi-Square test and Fisher’s Exact test
  5. Abbreviations: AGVI, Ahmed glaucoma valve implantation; BCVA, best-corrected visual acuity; IOP, intraocular pressure
  6. Group 1, Group of NVG patients who maintained an IOP of 30 mmHg or more before AGVI despite initial non-surgical treatment including maximum tolerable medical treatment; Group 2, Group of NVG patients who responded well to initial non-surgical treatment but eventually required AGVI.